Brief: Valbiotis Sets Out 2024 Commercial and Clinical Roadmap

Valbiotis SA

16/01/2024 16:43

Jan 16 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS SETS OUT ITS COMMERCIALAND CLINICAL ROADMAP FOR
2024
    * FRENCH MARKET LAUNCH OF TOTUM•070 (HYPERCHOLESTEROLEMIA)
CONFIRMED FOR FIRST HALF OF 2024
    * A NEW PHASE OF DEVELOPMENT IS OPENING UP FOR COMPANY, WITH
AT
LEAST ONE PRODUCT DUE FOR LAUNCH THIS YEAR
    * IN TERMS OF CLINICAL DEVELOPMENT, VALBIOTIS ANNOUNCES
LAUNCH OF
HEART 2 STUDY ON TOTUM•070 (HYPERCHOLESTEROLEMIA)
    * STRUCTURING OF INDUSTRIAL ACTIVITIES SOON TO BE FINALIZED
WITH A
VIEW TO NESTLÉ HEALTH SCIENCE'S FIRST ORDER FOR TOTUM•63
(PREDIABETES / TYPE 2 DIABETES)
    * FOLLOWED BY FUTURE WORLDWIDE OR REGIONAL LICENSING AND/OR
DISTRIBUTION PARTNERSHIPS FOR OTHER TOTUM PRODUCTS
    * CONTINUED CLINICAL DEVELOPMENT OF COMPANY'S PORTFOLIO TO
CONSOLIDATE ITS SCIENTIFIC VALUE
    * PLANS TO ANNOUNCE CLINICAL STRATEGY FOR TOTUM•448 AND
ASSOCIATED
ACADEMIC PARTNERSHIPS IN NON-DRUG TREATMENT OF METABOLIC LIVER
DISEASE (MASLD, FORMERLY NAFLD) SHORTLY

Source text for Eikon:  urn:newsml:reuters.com:*:nEQ44hTV1a
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))